title: Clinical study of l-asparaginase in the treatment of extranodal NK/T-cell lymphoma, nasal type.
abstract: Extranodal natural killer/T-cell lymphoma, nasal type, (ENKTL) is a rare distinct entity of non-Hodgkin lymphoma. It is prevalent in Asia and Latin America but rare in North America and Europe. ENKTL represents an aggressive clinical course and a poor prognosis especially for advanced disease. There is no standard chemotherapeutic regimen for ENKTL. Recently, the efficacy of l-asparaginase in ENKTL has been confirmed. A series of l-asparaginase-containing chemotherapeutic regimens have been studied in clinical trials and have significantly improved the efficacy and prognosis for patients with ENKTL. This review will focus on pharmacology of l-asparaginase, the efficacy of a series of l-asparaginase-containing regimens in the treatment of ENKTL and future clinical study directions of l-asparaginase-containing regimens in ENKTL. Copyright © 2015 John Wiley & Sons, Ltd.
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
authors.forename: Weiben
authors.initials: W
authors.lastname: Yong
mesh_terms: D001215:Asparaginase / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000188:drug therapy*; D008297:Male
chemical_list: D001215:Asparaginase
keywords: NK/T-cell lymphoma; efficacy; l-asparaginase